Summary
This review examined published articles from January 2022 to August 2023 on vitamin D in COVID-19 and long COVID-19 and on metformin. It included 58 clinical studies and described observational studies, randomized controlled trials and meta-analyses; articles were collected from electronic databases. Vitamin D was given in varied doses and durations, including 4,000 IU daily for 30 days, 10,000 IU/day for 14 days, 50,000 IU weekly for 2–3 weeks, 140,000 IU, 200,000 IU, 400,000 IU, 500 000 IU, and calcifediol 450 mcg each on two consecutive days. Comparisons included placebo, no supplementation, low versus high dose, and standard-dose cholecalciferol. Outcomes included SARS-CoV-2 infection, severity, ICU admission, mechanical ventilation, mortality, hospital stay, oxygen need and inflammatory markers. Some studies reported lower infection, severity, ICU admission, ventilation or mortality; others reported no effect, including Mariani et al. (218 adults), Jolliffe et al. (3100 participants), Zhang et al. (3359 patients), Abroug et al. (117 patients), and Cannata-Andía et al. Villasis-Keever et al. reported no serious AEs; Sarhan et al. reported fewer adverse outcomes compared with low-dose vitamin D. Metformin was reported with about 41% reduction in long Covid versus placebo. Worsening and stopping counts were not reported.